AstraZeneca
1,407
SEK
-0.14 %
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
27 following
-0.14%
-14.1%
-19.58%
-14.34%
+3.95%
+5.75%
+37.86%
+55.13%
+7,598.83%
www.astrazeneca.com/investor-relations.html
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and marketing of prescription drugs, primarily for the treatment of diseases in the areas of therapy that affect the respiratory tract, cardiovascular / metabolism, and cancer. In addition to its main operations, the company is also active in autoimmunity, neuroscience, and infection. AstraZeneca is active in all global regions and is headquartered in Cambridge.
Revenue
462.19B
EBIT %
17.88 %
P/E
36.32
Dividend yield-%
2.08 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
AZN
Daily low / high price
1,390 / 1,411
SEK
Market cap
2.18T SEK
Turnover
212.12M SEK
Volume
151K
Financial calendar
Annual report
2025-02-06
Interim report
2025-04-29
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| BlackRock, Inc. | 6.5 % | 6.5 % |
| Wellington Management Group | 4.2 % | 4.2 % |
| The Capital Group Companies | 4.1 % | 4.1 % |
| Investor AB | 3.3 % | 3.3 % |
ShowingAll content types
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca: Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools